Lilly raises outlook for third time this year as Zepbound sales soar.

The drug continues do dominate the market for prescription weight-loss drugs in the U.S.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.